Morocco continues to deepen its regulated cannabis ecosystem under Law 13‑21 (2021), with a March 2026 agreement between the Moroccan Agency for Medicines and Health Products (AMMPS) and the National Agency for the Regulation of Cannabis Activities (ANRAC) to establish procedures for registering cannabis‑derived health products. This protocol is designed to clarify how cannabis‑based medicines and related products move from cultivation licenses to market authorization, strengthening investor confidence in the medical channel.
In a separate but significant development, ANRAC has launched a 10‑month scientific study with the Hassan II Institute of Agronomy and Veterinary Medicine to evaluate cannabis‑derived molecules as alternatives to growth‑promoting antibiotics in poultry feed. If successful, this could open a new industrial use case beyond medical, cosmetic and traditional industrial applications, potentially broadening the addressable market for licensed operators.